Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Angina (Angina Pectoris) Pipeline Review, H2 2017 - Research and Markets

Research and Markets
Posted on: 19 Dec 17

The "Angina (Angina Pectoris) - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Angina (Angina Pectoris) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Angina (Angina Pectoris) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Angina (Angina Pectoris) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Angina (Angina Pectoris) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 1, 1 and 1 respectively.

Angina (Angina Pectoris) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Angina (Angina Pectoris) - Overview
  2. Angina (Angina Pectoris) - Therapeutics Development
  3. Pipeline Overview
  4. Pipeline by Companies
  5. Products under Development by Companies
  6. Angina (Angina Pectoris) - Therapeutics Assessment
  7. Assessment by Target
  8. Assessment by Mechanism of Action
  9. Assessment by Route of Administration
  10. Assessment by Molecule Type
  11. Angina (Angina Pectoris) - Companies Involved in Therapeutics Development
  • Angionetics Inc
  • Juventas Therapeutics Inc
  • Kuhnil Pharmaceutical Co Ltd
  • Sanofi
  • TSH Biopharm Corporation Ltd
  • ViroMed Co Ltd
  • XyloCor Therapeutics Inc

For more information about this report visit

View source version on

Business Wire

Last updated on: 19/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.